EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation

Christopher X Wong, Christopher C Cheung, Gabrielle Montenegro, Hannah H Oo, Isabella J Peña, Janet J Tang, Samuel J Tu, Grace Wall, Thomas A Dewland, Joshua D Moss, Edward P Gerstenfeld, Zian H Tseng und 8 weitere

JAMA · 27.01.2026 · 335 (4) · 317

DOI: 10.1001/jama.2025.21056 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 27.01.2026. Verfasst von Christopher X Wong und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of California San Francisco. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Flutter, Caffeine, Coffee. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed.

Objective

To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF. Design, Setting, and Participants This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025.

Intervention

Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products. Main Outcomes and Measures The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months.

Results

Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n = 100) or coffee abstinence (n = 100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89]; P = .01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events. Conclusions and Relevance In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products. Trial Registration ClinicalTrials.gov Identifier: NCT05121519

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAtrial FlutterCaffeineCoffeeAgedFemaleHumansMaleMiddle AgedProspective StudiesRecurrenceSecondary PreventionElectric CountershockFollow-Up StudiesIncidenceAged, 80 and over

Substanzen

CaffeineCoffee

Autor:innen und Institutionen

  • Division of Cardiology, University of California San Francisco.
  • Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Department of Epidemiology and Biostatistics, University of California San Francisco.

Zitieren

APA

Wong, C. X., Cheung, C. C., Montenegro, G., Oo, H. H., Peña, I. J., Tang, J. J., Tu, S. J., Wall, G., Dewland, T. A., Moss, J. D., Gerstenfeld, E. P., Tseng, Z. H., Hsia, H. H., Lee, R. J., Olgin, J. E., Vedantham, V., Scheinman, M. M., Lee, C., Sanders, P., & Marcus, G. M. (2026). Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation. JAMA, 335(4), 317. https://doi.org/10.1001/jama.2025.21056

Vancouver

Wong CX, Cheung CC, Montenegro G, Oo HH, Peña IJ, Tang JJ, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation. JAMA. 2026;335(4):317. doi:10.1001/jama.2025.21056

BibTeX
@article{Wong2026,
  author = {Wong, Christopher X and Cheung, Christopher C and Montenegro, Gabrielle and Oo, Hannah H and Peña, Isabella J and Tang, Janet J and Tu, Samuel J and Wall, Grace and Dewland, Thomas A and Moss, Joshua D and Gerstenfeld, Edward P and Tseng, Zian H and Hsia, Henry H and Lee, Randall J and Olgin, Jeffrey E and Vedantham, Vasanth and Scheinman, Melvin M and Lee, Catherine and Sanders, Prashanthan and Marcus, Gregory M},
  title = {Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {4},
  pages = {317},
  doi = {10.1001/jama.2025.21056}
}
Kostenlos starten →